Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia

Annals of the New York Academy of Sciences

Volumn 1075, Issue , 2006, Pages 222-229

  Müller, Imke ^a   Urban, Karoline ^a   Pantel, Klaus ^a   Schwarzenbach, Heidi ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

BPH; Circulating tumor DNA; Loss of heterozygosity (LOH); Microsatellite aberrations; Prostate cancer

Indexed keywords

GENOMIC DNA; MICROSATELLITE DNA; MOLECULAR MARKER; PROSTATE SPECIFIC ANTIGEN;

BLOOD LEVEL; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER SCREENING; CELL FREE SYSTEM; CHROMOSOME 11Q; CHROMOSOME 3P; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME ANALYSIS; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DNA CONTENT; DNA DETERMINATION; DNA EXTRACTION; GENE MAPPING; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NULL ALLELE; PROSTATE CANCER; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

EID: 33749576333     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1368.030     Document Type: Conference Paper

References (27)

1. CATALONA, W.J. et al. 1994. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J. Urol. 151: 1283-1290.
2. STAMEY, T.A. et al. 2004. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J. Urol. 172: 1297-1301.
3. ELO, J.P. & T. VISAKORPI. 2001. Molecular genetics of prostate cancer. Ann. Med. 33: 130-141.
4. SARIC, T. et al. 1999. Genetic pattern of prostate cancer progression. Int. J. Cancer 81: 219-224.
5. NUPPONEN, N.N. & T. VISAKORPI. 2000. Molecular cytogenetics of prostate cancer. Microsc. Res. Tech. 51: 456-463.
6. VON KNOBLOCH, R. et al. 2004. Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping. Clin. Cancer Res. 10: 1064-1073.
7. DONG, J.T. 2001. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev. 20: 173-193.
8. DONG, J.T. et al. 2001. Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate 49: 166-171.
9. JENKINS, R. et al. 1998. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes Chromosomes Cancer 21: 131-143.
10. JUNG, K. et al. 2004. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. Cancer Lett. 205: 173-180.
11. WU, T.L. et al. 2002. Cell-free DNA: measurement in various carcinomas and establishment of normal reference range. Clin. Chim. Acta 321: 77-87.
12. BODDY, J.L. et al. 2005. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin. Cancer Res. 11: 1394-1399.
13. STROUN, M. et al. 2001. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta 313: 139-142.
14. JAHR, S. et al. 2001. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61: 1659-1665.
15. SCHWARZENBACH, H. et al. 2004. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer: circulating nucleic acids in plasma/serum proteomics III. Ann. N. Y. Acad. Sci. 1022: 25-32.
16. SILVA, J.M. et al. 2002. Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin. Cancer Res. 8: 3761-3766.
17. CHEN, X.Q. et al. 1999. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin. Cancer Res. 5: 2297-2303.
18. CHEN, X.Q. et al. 1996. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat. Med. 2: 1033-1035.
19. ANKER, P. et al. 1997. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 112: 1114-1120.
20. GOESSL, C. et al. 1998. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma. Cancer Res. 58: 4728-4732.
21. NAWROZ, H. et al. 1996. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med. 2: 1035-1037.
22. TABACK, B. et al. 2001. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res. 61: 5723-5726.
23. OZEN, M. & S. PATHAK. 2000. Genetic alterations in human prostate cancer: a review of current literature. Anticancer Res. 20: 1905-1912.
24. TAL-OR, P. et al. 2003. Neuregulin promotes autophagic cell death of prostate cancer cells. Prostate 55: 147-157.
25. FROMONT, G. et al. 2003. Allelic losses in localized prostate cancer: association with prognostic factors. J. Urol. 170: 1394-1397.
26. PERINCHERY, G. et al. 1999. High frequency of deletion on chromosome 9p21 may harbour several tumor-suppressor genes in human prostate cancer. Int. J. Cancer 83: 610-614.
27. KATO, Y. et al. 2004. A tumor suppressor role for thyroid hormone beta-receptor in a mouse model of thyroid carcinogenesis. Endocrinology 145: 4430-4438.